Albumin-bound paclitaxel plus gemcitabine for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have pancreatic cancer that cannot be removed by surgery (locally advanced or spread/metastatic), not including islet cell tumors
- Have not had standard chemotherapy drugs before, or stopped standard treatment more than 6 months ago (and any major surgery/radiation must be more than 4 weeks ago with no further local treatment to metastases)
- Have at least one measurable tumor spot on a CT scan (size thresholds must be met)
- Have enough healthy organ function based on blood and organ tests (blood counts, liver tests, and kidney function)
- Be able and willing to sign consent and come back for follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of anlotinib (a targeted drug), benmelstobart (an immunotherapy), and AG chemotherapy as a first treatment for advanced pancreatic cancer that has spread to other parts of the body. The goal is to see if this triple therapy can help shrink or control the cancer better than standard treatments.
This trial tests a combination of three chemotherapy drugs (irinotecan liposome, albumin-bound paclitaxel, and gemcitabine) as a first treatment for people with pancreatic cancer that has not spread to the brain. It aims to see if this combination works better than standard treatments.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy before surgery for pancreatic cancer that can be removed. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a new form of the chemotherapy drug paclitaxel (called polymeric micellar paclitaxel) for people with pancreatic cancer that has spread to other parts of the body (metastatic). It's for those who haven't had any prior treatment for their metastatic cancer, and aims to see if this drug can help control the cancer.
This trial tests whether a home-wearable tumor-treating device (Tumor Treating Fields) combined with gemcitabine and albumin-bound paclitaxel works better as first treatment for locally advanced pancreatic cancer. It may help by targeting cancer cells while also using standard chemotherapy.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.